Novo Nordisk's CagriSema Falls Short Against Eli Lilly's Tirzepatide in Obesity Trial
核心洞察
Novo Nordisk's next-generation obesity (搜索) drug CagriSema achieved 20.2% weight loss after 84 weeks, falling short of Eli Lilly's tirzepatide at 23.6% in head-to-head comparison.
The trial failed to meet its primary endpoint of demonstrating non-inferiority to tirzepatide, marking a significant setback for Novo's obesity (搜索) strategy.
Novo shares plunged 15.4% following the announcement, while Eli Lilly shares rose 4.2% in premarket trading.
Novo Nordisk's next-generation obesity (搜索) treatment CagriSema delivered disappointing weight-loss results in a pivotal trial, achieving 20.2% average weight reduction after 84 weeks compared to 23.6% for Eli Lilly's competing drug tirzepatide. The Danish pharmaceutical giant announced Monday that the trial failed to meet its primary endpoint of demonstrating non-inferiority to Lilly's treatment, dealing a significant blow to Novo's obesity drug strategy.
Market Response and Competitive Impact
Following the announcement, Novo Nordisk shares plummeted as much as 15.4% in Copenhagen trading, while Eli Lilly shares surged 4.2% in premarket US trading. The stark market reaction reflected investor disappointment over CagriSema's relative underperformance against a key competitor in the rapidly expanding obesity (搜索) drug market.
Despite Novo's assertion that CagriSema appeared safe and well-tolerated throughout the 84-week study period, the efficacy gap with tirzepatide overshadowed these safety findings. Tirzepatide serves as the active ingredient in Lilly's blockbuster medications Mounjaro and Zepbound, which have already overtaken Novo's semaglutide-based drugs Ozempic and Wegovy in US prescriptions.
Strategic Implications for CagriSema
CagriSema represents a cornerstone of Novo Nordisk's long-term obesity (搜索) strategy, particularly as newer, more powerful treatments enter the market and patents for Wegovy and Ozempic approach expiry. The investigational injection combines semaglutide with cagrilintide, a compound that mimics the gut hormone amylin (搜索), designed to enhance appetite suppression and improve weight-loss outcomes.
UBS (搜索) analyst Colin White had noted before the results that the base-case expectation was that CagriSema would at least not perform worse than Zepbound. "The base case for the trial was that the newer Novo drug wouldn't be worse than Zepbound," White stated, making the outcome a clear disappointment relative to earlier expectations.
Leadership Changes Amid Competitive Pressure
The trial setback occurs against a backdrop of significant organizational changes at Novo Nordisk. Over the past year, the company has replaced its chief executive and experienced board-level departures amid concerns over competitive performance. Former head of international operations Mike Doustdar was elevated to chief executive following the previous CEO's departure.
Since assuming leadership, Doustdar has implemented thousands of job cuts and mandated staff return to office policies in efforts to restore performance standards. He also pursued an unsuccessful bid for obesity (搜索) startup Metsera, ultimately losing to Pfizer. Doustdar has since indicated that Novo will go "very big" in its search for future obesity deals.
Financial Performance and Market Valuation
Novo Nordisk shares have declined more than 58% over the past 12 months, reducing the company's market value to approximately $189 billion. In 2024, the company was briefly valued at more than $600 billion, highlighting the dramatic shift in investor sentiment.
The company continues to explore additional trials, including higher-dose combinations, to improve treatment outcomes. Novo maintains high hopes for CagriSema despite the latest setback, though the results underscore the growing challenge the company faces in keeping pace with Lilly in a market where incremental differences in weight loss can have major commercial consequences.
Subsequent Market Developments
In a separate development, Novo Nordisk shares rose more than 3% in late afternoon trading following Eli Lilly's study results on its next-generation obesity (搜索) drug retatrutide. J.P. Morgan noted that retatrutide achieved 23.7% weight loss on an intention-to-treat basis, roughly 3% higher than Novo's CagriSema. Kepler Cheuvreux deemed these results "very mixed," potentially providing some relief to investors as Novo expectations have been very low.